Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sabre Insurance see growth softening as competition picks up

(Sharecast News) - Shares in Sabre Insurance fell sharply on Tuesday after UK motor insurance underwriting firm warned of a "slight softening" in pricing this year, despite the company remaining on track for record premium income. Gross written premiums totalled £186.5m for the nine months to 30 September, up 15% on the year before, as the company continues to increase rates to cover elevated claims inflation.

Sabre had written 230,000 motor policies by the end of the period, up from 222,000 a year earlier, while the number of motorcycle and taxi policies dipped to 38,000 and 11,000, from 45,000 and 13,000 respectively. Nevertheless, policies continue to be written at target margins, the company said, underpinning profitable growth this year.

Claims inflation remains at the high singe-digit level, but there are some signs of moderation. However, increased competition for volumes in the mass-market has been evident with reductions in market prices.

While Sabre still expects strong growth in premiums this year, and profit in line with market forecasts, growth is expected to have moderated slightly.

"We have seen clear signs that market pricing has softened considerably during the summer. Our view is that market price movements outstrip any potential short-term benefits from a slight softening in claims inflation," said chief executive Geoff Carter.

"We remain confident in our view on inflation and that market pricing will have to reflect this in due course."

The stock was down 9% at 125p by 1059 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.